Home

Depression

Depression, Schizophrenia

Read time: 4 min

Congress highlights

Towards new treatment options for MDD and schizophrenia: a role for D2 receptor partial agonists

Major depressive disorder (MDD) and schizophrenia share in common the side effect burden associated...

Depression, Schizophrenia

What are you doing to celebrate World Mental Health Day?

We asked advocacy groups from all around the world why it is important to support World Mental...

Read time: 3 min

Congress highlights

A “syndemic” relationship: Managing depression and diabetes

There is a high level of major depression among people with diabetes, and people with major...

Read time: 4 min

Congress highlights

Do we have enough psychiatry training in medical education? A Global Perspective

Psychiatric disorders comprise a global public health priority as standalone conditions and are...

Read time: 3 min

Brain circuits in depression and response to pharmacotherapy

The symptoms of major depressive disorder (MDD) vary from patient to patient. The primary treatment...

Depression, Schizophrenia

Read time: 1 min

How can you support carers for people with schizophrenia and psychosis?

More than 25.000 carers have already signed up to The Carer Academy, an interactive online course...

Read time: 6 min

New understanding of the gut microbiome may be the key to many diseases and pave the way for new therapies

The role of the gut microbiome in a range of psychiatric disorders, including depression and...

Depression, Bipolar

Read time: 3 min

Predicting vulnerability to mood disorders and treatment response

Major depressive disorder (MDD) is ultimately about how the brain responds to the environment, but...

Depression, Schizophrenia

Read time: 6 min

ICD-11 – fielding for diagnostic success

In 2018, the World Health Organization (WHO) will release two important documents, both of which...

Read time: 4 min

Congress highlights

Antidepressant controversies re-examined

This meeting brought together four speakers who have examined and re-evaluated data from the huge...

Depression, Schizophrenia

Read time: 3 min

Congress highlights

Why do we need new treatments for major depressive disorder and schizophrenia?

Atypical antipsychotics are the mainstay of treatment for schizophrenia and a therapeutic option as...

Read time: 4 min

Congress highlights

Mutual benefits: Public–Private Partnerships in CNS Research

Public–Private Partnerships are being developed worldwide to facilitate collaboration between...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country